{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T18:17:01Z","timestamp":1787509021392,"version":"build-2736575974"},"reference-count":34,"publisher":"Microbiology Society","issue":"1","license":[{"start":{"date-parts":[[2025,1,7]],"date-time":"2025-01-07T00:00:00Z","timestamp":1736208000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100012543","name":"Shanghai Science and Technology Development Foundation","doi-asserted-by":"crossref","award":["20MC1920100"],"award-info":[{"award-number":["20MC1920100"]}],"id":[{"id":"10.13039\/100012543","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100017950","name":"Shanghai Municipal Health Commission","doi-asserted-by":"crossref","award":["shslczdzk01102"],"award-info":[{"award-number":["shslczdzk01102"]}],"id":[{"id":"10.13039\/100017950","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,1,7]]},"abstract":"<jats:p>\n                    <jats:bold>Introduction.<\/jats:bold>\n                    Lamivudine plus dolutegravir (3TC\/DTG) and bictegravir\/emtricitabine\/tenofovir alafenamide (B\/F\/TAF) regimens are commonly used as first-line treatments for people living with human immunodeficiency virus (HIV) (PLWH) worldwide.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Gap Statement.<\/jats:bold>\n                    There are limited comparative data on the antiviral activity and safety between these regimens in ART-naive PLWH, particularly in China, where the 3TC\/DTG regimen was integrated into first-line therapy in 2021 and gained broader adoption after its inclusion in the National Health Insurance in 2022.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Aims.<\/jats:bold>\n                    This study aims to provide real-world evidence comparing the 3TC\/DTG regimen to the B\/F\/TAF regimen in ART-naive PLWH in China.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Methodology.<\/jats:bold>\n                    This retrospective study enrolled PLWH initiating ART with either 3TC\/DTG or B\/F\/TAF in Shanghai from January 2020 to January 2023. Demographic characteristics and clinical information were collected and compared for each patient.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Results.<\/jats:bold>\n                    A total of 380 eligible, ART-naive PLWH were included, with 190\u2009patients in the 3TC\/DTG group and 190\u2009patients in the B\/F\/TAF group. Following the initiation of ART, most patients (94.1 and 89.3% for 3TC\/DTG and B\/F\/TAF groups, respectively) achieved viral suppression (&lt;50 copies of HIV RNA per millilitre) at week 24. The CD4 cell count significantly increased from a baseline of 301.3\u00b1185.8\u2009cells per microlitre to 479.5\u00b1229.3\u2009cells per microlitre at week 36 for the 3TC\/DTG group and from 289.2\u00b1188.8\u2009cells per microlitre at baseline to 487.8\u00b1234.2\u2009cells per microlitre at week 36 for the B\/F\/TAF group. Both groups experienced an increase in blood lipid levels after initiating ART, with higher levels of high-density lipoprotein cholesterol (HDL-C) observed in the 3TC\/DTG group compared with the B\/F\/TAF group. Renal and hepatic function indicators remained stable in both groups.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Conclusions.<\/jats:bold>\n                    3TC\/DTG demonstrates similar antiviral efficacy to B\/F\/TAF and does not significantly impact liver and kidney functions. Patients receiving 3TC\/DTG showed higher plasma HDL-C levels compared with those on B\/F\/TAF, which confer long-term clinical benefits in reducing cardiovascular risk.\n                  <\/jats:p>","DOI":"10.1099\/jmm.0.001949","type":"journal-article","created":{"date-parts":[[2025,1,7]],"date-time":"2025-01-07T09:17:35Z","timestamp":1736241455000},"source":"Crossref","is-referenced-by-count":7,"title":["Safety and efficacy of lamivudine\/dolutegravir vs. bictegravir\/emtricitabine\/tenofovir alafenamide in antiretroviral-naive adults with HIV-1 infection in Shanghai, China: a single-centre retrospective study"],"prefix":"10.1099","volume":"74","author":[{"given":"Junyang","family":"Yang","sequence":"first","affiliation":[{"name":"Department of Infection and Immunology, Shanghai Public Health Clinical Center, Fudan University, Shanghai, PR China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Nursing, Shanghai Public Health Clinical Center, Fudan University, Shanghai, PR China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoran","family":"Zhang","sequence":"additional","affiliation":[{"name":"No. 2 High School of East China Normal University, SongJiang, Shanghai, PR China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Infection and Immunology, Shanghai Public Health Clinical Center, Fudan University, Shanghai, PR China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinzhong","family":"Shen","sequence":"additional","affiliation":[{"name":"Department of Infection and Immunology, Shanghai Public Health Clinical Center, Fudan University, Shanghai, PR China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tangkai","family":"Qi","sequence":"additional","affiliation":[{"name":"Department of Infection and Immunology, Shanghai Public Health Clinical Center, Fudan University, Shanghai, PR China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenyan","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Infection and Immunology, Shanghai Public Health Clinical Center, Fudan University, Shanghai, PR China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Song","sequence":"additional","affiliation":[{"name":"Department of Infection and Immunology, Shanghai Public Health Clinical Center, Fudan University, Shanghai, PR China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Tang","sequence":"additional","affiliation":[{"name":"Department of Infection and Immunology, Shanghai Public Health Clinical Center, Fudan University, Shanghai, PR China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuibao","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Infection and Immunology, Shanghai Public Health Clinical Center, Fudan University, Shanghai, PR China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianjun","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Infection and Immunology, Shanghai Public Health Clinical Center, Fudan University, Shanghai, PR China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youming","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Infection and Immunology, Shanghai Public Health Clinical Center, Fudan University, Shanghai, PR China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yihong","family":"Shen","sequence":"additional","affiliation":[{"name":"Department of Community, Shanyang Community Health Service Center, Shanghai, PR China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Infection and Immunology, Shanghai Public Health Clinical Center, Fudan University, Shanghai, PR China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renfang","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Infection and Immunology, Shanghai Public Health Clinical Center, Fudan University, Shanghai, PR China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"345","reference":[{"key":"R1","doi-asserted-by":"publisher","DOI":"10.1007\/s11904-019-00478-x"},{"key":"R2","doi-asserted-by":"publisher","DOI":"10.1002\/path.4449"},{"key":"R3","doi-asserted-by":"publisher","DOI":"10.3390\/v15122432"},{"key":"R4","doi-asserted-by":"publisher","DOI":"10.1016\/j.cpcardiol.2023.102353"},{"key":"R5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2019.03.034"},{"key":"R6","doi-asserted-by":"publisher","DOI":"10.2174\/1570162X20666220514165728"},{"key":"R7","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000031100"},{"key":"R8","doi-asserted-by":"publisher","DOI":"10.1097\/CM9.0000000000002907"},{"key":"R9","article-title":"Guidelines for the use of antiretroviral agents in adults and adolescents with HIV","year":"2024"},{"key":"R10","article-title":"EACS guidelines version 12.0","year":"2023"},{"key":"R11","doi-asserted-by":"publisher","DOI":"10.1111\/hiv.13446"},{"key":"R12","first-page":"203","volume-title":"Chinese Guidelines for Diagnosis and Treatment of Human Immunodeficiency Virus Infection\/Acquired Immunodeficiency Syndrome (2021 edn)","year":"2021"},{"key":"R13","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2006040368"},{"key":"R14","doi-asserted-by":"publisher","DOI":"10.1007\/s40121-021-00522-7"},{"key":"R15","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000002285"},{"key":"R16","doi-asserted-by":"publisher","DOI":"10.1080\/14787210.2022.2128766"},{"key":"R17","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciac130"},{"key":"R18","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz1243"},{"key":"R19","doi-asserted-by":"publisher","DOI":"10.1080\/21505594.2021.2004743"},{"key":"R20","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkv099"},{"key":"R21","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1000321"},{"key":"R22","doi-asserted-by":"publisher","DOI":"10.1086\/650749"},{"key":"R23","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10163456"},{"key":"R24","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2023.101991"},{"key":"R25","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1409065"},{"key":"R26","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(19)30003-8"},{"key":"R27","doi-asserted-by":"publisher","DOI":"10.1038\/nrcardio.2010.222"},{"key":"R28","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines9091083"},{"key":"R29","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21030732"},{"key":"R30","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2011.01.022"},{"key":"R31","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofw053"},{"key":"R32","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000003434"},{"key":"R33","doi-asserted-by":"publisher","DOI":"10.1097\/MNH.0000000000000400"},{"key":"R34","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciac949"}],"container-title":["Journal of Medical Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.microbiologyresearch.org\/content\/journal\/jmm\/10.1099\/jmm.0.001949?crawler=true&mimetype=application\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,7]],"date-time":"2025-01-07T09:17:39Z","timestamp":1736241459000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.microbiologyresearch.org\/content\/journal\/jmm\/10.1099\/jmm.0.001949"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,7]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1,7]]}},"URL":"https:\/\/doi.org\/10.1099\/jmm.0.001949","relation":{},"ISSN":["0022-2615","1473-5644"],"issn-type":[{"value":"0022-2615","type":"print"},{"value":"1473-5644","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,7]]}}}